EMAIL THIS PAGE TO A FRIEND

Cancer research

Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein.


PMID 24755468

Abstract

Aberrant von Hippel Lindau (VHL) protein function is the underlying driver of VHL-related diseases, including both sporadic and inherited clear cell renal cell carcinoma (ccRCC). About one third of VHL mutations are missense point mutations, with R167Q being the most common VHL point mutation in hereditary VHL disease. Although it has been studied extensively, the ability of VHL-R167Q to downregulate hypoxia-inducible factor 2α (HIF2α) is still controversial. In addition, the manner in which the mutation contributes to tumorigenesis is not fully understood. No therapeutic approach is available to target VHL-R167Q and similar missense point mutations. We analyzed VHL-R167Q proteostasis and function at normoxia, at hypoxia with different oxygen pressure, and in a xenograft mouse model. We showed that the protein levels of VHL-R167Q dictate its ability to downregulate HIF2α and suppress tumor growth. Strikingly, the proteasome inhibitors bortezomib and carfilzomib, which are currently in clinical use, stabilize VHL-R167Q and increase its ability to downregulate HIF2α. VHL-R167Q binds elongin C and elongin B with considerably less avidity than wild-type VHL does but retains residual capacity to generate a VHL-elongin C-elongin B complex, downregulate HIF2α, and suppress tumorigenesis, which could be rescued by increase of VHL-R167Q levels. Finally, we used in silico approaches and identified other missense VHL mutants in addition to VHL-R167Q that might be rescued by similar strategies. Thus, our studies revealed detailed information describing how VHL-R167Q contributes to tumorigenesis and identified a potential targeted therapy for ccRCC and other VHL-related disease in patients carrying VHL-R167Q or similar missense mutations.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

GW22763 Anti-GAPDH antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB3500247
Anti-GAPDH antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB1405848
Anti-GAPDH antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB2701826
Anti-gapdh antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2701825
Anti-gapdh antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2103104
Anti-GAPDH antibody produced in rabbit, affinity isolated antibody, lyophilized powder
SAB4300645
Anti-GAPDH antibody produced in rabbit, affinity isolated antibody
HPA040067
Anti-GAPDH antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1409726
Anti-TCEB2 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
AV31323
Anti-TCEB2 antibody produced in rabbit, affinity isolated antibody
SAB2501099
Anti-VHL antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1406582
Anti-VHL antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB4200434
Anti-VHL antibody produced in rabbit, ~1.0 mg/mL, affinity isolated antibody
SAB4503075
Anti-VHL antibody produced in rabbit, affinity isolated antibody
PLA0302
Goat anti-GAPDH Antibody, Affinity Purified, Powered by Bethyl Laboratories, Inc.
WH0002597M1
Monoclonal Anti-GAPDH antibody produced in mouse, clone 3C2, purified immunoglobulin, buffered aqueous solution
WH0006923M1
Monoclonal Anti-TCEB2 antibody produced in mouse, clone 6F6, purified immunoglobulin, buffered aqueous solution
SAB1404447
Monoclonal Anti-TCEB2 antibody produced in mouse, clone 2B4, purified immunoglobulin, buffered aqueous solution
WH0007428M1
Monoclonal Anti-VHL antibody produced in mouse, clone 1G12, purified immunoglobulin, buffered aqueous solution
PLA0125
Rabbit anti-GAPDH Antibody, Affinity Purified, Powered by Bethyl Laboratories, Inc.